Abstract:Dear Editor, Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with a wide variety of presenting features. Many studies have suggested cytokines are involved in the pathogenesis of SLE.1-4 Interleukin (IL)-35, a heterodimeric cytokine composed of the subunits EBI3 and p35, was recently identified as a new member of the IL-12 cytokine family.5 The role of IL-35 remains controversial in inflammatory diseases. Some studies have shown its anti-inflammatory properties given its effect on Treg, regulator B cells and associated cytokines in inflammatory bowel disease, collagen-induced arthritis or other autoimmune diseases.6-8 In contrast, IL-35 enhanced the inflammatory response in Lyme arthritis9 and IL-35 gene therapy exacerbates experimental rheumatoid arthritis in mice.10 The expression and significance of IL-35 in patients with SLE is still obscure. Several studies have shown that the level of IL-35 was decreased and the percentage of CD4+ EBI3+ T cells were also significantly decreased in patients with active SLE.11, 12 Another study showed that plasma IL-35 and soluble gp130 levels were significantly higher in patients with severe SLE.13 We conducted this study to investigate the IL-35 level in patients with SLE and their potential association with clinical manifestations and disease activity. We enrolled 145 patients with SLE (133 females and 12 males, mean age 35.6 ± 13.9 years) and 69 age- and sex-matched healthy volunteers without diseases. The protocol for the study was approved by the Ethics Committee of Peking University People's Hospital (FWA00001384). Clinical and laboratory features of SLE patients were recorded. Serum levels of IL-35 were measured by enzyme-linked immunosorbent assay according to the manufacturer's protocol (USCN Life Science, Wuhan, China). The levels of serum IL-35 were significantly higher in patients with SLE than in healthy controls (125.7 ± 110.5 vs. 19.1 ± 45.4, t = 10.050, P = 0.0000) (Fig. 1). The levels of IL-35 were significantly higher in SLE patients with SLE Disease Activity Index (SLEDAI) scores ≥ 8 than patients with SLEDAI score < 8 (85.29 vs. 54.57, Z = −4.314, P = 0.000). The levels of serum IL-35 were correlated with anti-double-stranded DNA antibodies (r = 0.214, P = 0.010) and SLEDAI scores(r = 0.326, P = 0.000) (Fig. 2). The levels of serum IL-35 decreased significantly in accordance with disease activity after treatment in a subgroup of 19 patients with SLE (Fig. 3). Serum levels of IL-35 were associated with photosensitivity (115.5 ± 96.2 vs. 194.1 ± 170.5, t = −2.945, P = 0.004), arthritis (109.8 ± 104.5 vs. 161.4 ± 118.5, t = −2.636, P = 0.009) and fever (109.3 ± 103.9 vs. 161.3 ± 119.1, t = −2.672, P = 0.008) (Table 1). We could see that IL-35 levels were lower in SLE patients with antiphospholipid syndrome (APS) than those without APS, but there was no statistical difference between these two groups. In conclusion, we demonstrate circulating IL-35 is significantly higher than healthy controls and associate with disease activity in SLE. IL-35 might be involved in the pathogenesis of SLE. This work was supported by the National Nature Science Foundation of China (grant no. NSFC.81202297). The authors have no conflicts of interest to declare.

Serum Cyr61 is Associated with Clinical Disease Activity and Inflammation in Patients with Systemic Lupus Erythematosus

Dysregulated T Cell Activation and Aberrant Cytokine Expression Profile in Systemic Lupus Erythematosus.

Aberrant T Cell Subsets and Cytokines Expression Profile in Systemic Lupus Erythematosus.

156 Elevated Cysteine-Rich Protein 61 in Systemic Lupus Erythematosus-Associated Pulmonary Arterial Hypertension

Cysteine-rich Protein 61 As a Novel Biomarker in Systemic Lupus Erythematosus-Associated Pulmonary Arterial Hypertension

Cysteine-rich 61 (cyr61): a Biomarker Reflecting Disease Activity in Rheumatoid Arthritis.

AB0243 CYSTEINE RICH 61 (CYR61): A POTENTIAL BIOMARKER ASSOCIATED WITH DISEASE ACTIVITY IN RHEUMATOID ARTHRITIS

Levels of Soluble Interleukin-2 Receptor and Clinical Significance in Patients with Systemic Lupus Erythematosus

[Increased Serum C-C Chemokine Ligand 19 Levels Correlated with B Cell Abnormalities in Systemic Lupus Erythematosus].

Chemokine CXCL1 as a potential marker of disease activity in systemic lupus erythematosus

Cysteine Rich 61 in Autoimmune Diseases

Therapeutic potential of cysteine-rich protein 61 in rheumatoid arthritis.

The Clinical Significance of Soluble Axl and Tyro3 Receptor Tyrosine Kinase in Systemic Lupus Erythematosus

Serum Level of Anti-Monomer C-reactive Protein Antibody in Systemic Lupus Erythematosus

Serum Interleukin-2 Receptor Α As a Clinical Biomarker in Patients with Systemic Lupus Erythematosus

Increased Urinary Interleukin 22 Binding Protein Levels Correlate with Lupus Nephritis Activity

Serum levels of CXCL5 are decreased and correlate with circulating platelet counts in systemic lupus erythematosus

Cyr61 promotes proliferation of fibroblast-like synoviocytes in rheumatoid arthritis and its regulation by inflammatory factor

Elevated Serum Interleukin-35 Is Associated With Disease Activity In Patients With Systemic Lupus Erythematosus

Serum Uric Acid Combined with Homocysteine as a Predictive Biomarker of Lupus Nephritis

Cytokine Profiling in Chinese SLE Patients: Correlations with Renal Dysfunction